Forbes rich list released… #1 to be assassinated?

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Joseph Zakrzewski Biography and Net Worth

Director of Amarin

Joseph S. Zakrzewski joined Amarin in January 2010 as Executive Chairman and served as Amarin’s CEO from November 2010 until the end of December 2013 when he retired from his executive roles and while remaining as a member of the Board of Directors. Mr. Zakrzewski has more than 20 years of industry experience, including significant contributions to Reliant Pharmaceuticals as Chief Operating Officer during the period when Omacor®/Lovaza® was successfully developed, launched, and marketed for reducing very high triglyceride levels, leading to its 2007 acquisition by GlaxoSmithKline. In addition, Mr. Zakrzewski contributed 17 years of service to Eli Lilly & Company in a variety of capacities, including Vice President of Corporate Business Development where he had global responsibility for licensing activities. Mr. Zakrzewski also serves on the Boards of Acceleron Pharma and Insulet Corporation.

What is Joseph S. Zakrzewski's net worth?: The estimated net worth of Joseph S. Zakrzewski is at least $58,643.21 as of November 27th, 2024. Mr. Zakrzewski owns 125,199 shares of Amarin stock worth more than $58,643 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. Zakrzewski may own. Learn More about Joseph S. Zakrzewski's net worth.
How do I contact Joseph S. Zakrzewski?: The corporate mailing address for Mr. Zakrzewski and other Amarin executives is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. Amarin can also be reached via phone at (531) 669-9020 and via email at [email protected]. Learn More on Joseph S. Zakrzewski's contact information.
Has Joseph S. Zakrzewski been buying or selling shares of Amarin?: Joseph S. Zakrzewski has not been actively trading shares of Amarin over the course of the past ninety days. Most recently, on Tuesday, December 14th, Joseph S. Zakrzewski bought 10,000 shares of Amarin stock. The stock was acquired at an average cost of $3.27 per share, with a total value of $32,700.00. Learn More on Joseph S. Zakrzewski's trading history.
Who are Amarin's active insiders?: Amarin's insider roster includes Michael Kalb (CFO), Joseph Kennedy (General Counsel), Steven Ketchum (Insider), David Stack (Director), and Joseph Zakrzewski (Director). Learn More on Amarin's active insiders.
Are insiders buying or selling shares of Amarin?: During the last twelve months, Amarin insiders bought shares 2 times. They purchased a total of 174,426 shares worth more than $118,124.34. The most recent insider tranaction occured on August, 2nd when CEO Aaron Berg bought 160,000 shares worth more than $102,400.00. Insiders at Amarin own 2.0% of the company. Learn More about insider trades at Amarin.
Information on this page was last updated on 8/2/2024.

Joseph S. Zakrzewski Insider Trading History at Amarin

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/14/2021	Buy	10,000	$3.27	$32,700.00
7/5/2019	Sell	100,000	$23.82	$2,382,000.00
6/18/2019	Sell	100,000	$19.02	$1,902,000.00
1/2/2019	Sell	526,500	$13.07	$6,881,355.00
9/24/2018	Sell	500,000	$10.60	$5,300,000.00

Joseph S. Zakrzewski Buying and Selling Activity at Amarin

Amarin Company Overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Today's Range

Now: $0.47

$0.47

$0.50

50 Day Range

MA: $0.54

$0.46

$0.63

2 Week Range

Now: $0.47

$0.45

$1.37

Volume

2,603,726 shs

Average Volume

1,546,349 shs

Market Capitalization

$192.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83